Product Details
| Product Name:
PI3K/mTOR Inhibitor-7 |
CAS No.:
2456295-65-9 |
| Supply Ability:
10g |
Release date:
2026/01/05 |
Product Introduction
Bioactivity
| Name | PI3K/mTOR Inhibitor-7 |
| Description | PI3K/mTOR Inhibitor-7 is a potent dual PI3K/mTOR inhibitor. PI3K/mTOR Inhibitor-7 is 4.7-fold more potent than gedatolisib, with IC50 values of 1.4 μM and 0.3 μM, respectively. 10 μM of PI3K/mTOR Inhibitor-7 is able to significantly inhibit the PI3K/Akt/mTOR signalling pathway. PI3K/mTOR Inhibitor-7 has shown potential for research in cancer diseases. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Inhibitors Related | Musk ketone | Stearamide | Myricetin | Creatine monohydrate | Hyaluronic acid | 4-Methylbenzylidene camphor | N-Hydroxyphthalimide | L-Proline | Isoprenaline hydrochloride | Methyl eugenol | Metformin hydrochloride | Dihydromyricetin |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries, 10000+ Noval Small Molecucles,16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
-
CAS:1482494-72-3
$2180.00 / 50mg
-
CAS:117773-39-4
$1520.00 / 25mg
-
CAS:120688-08-6
$1520.00 / 25mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |